166 related articles for article (PubMed ID: 35666052)
1. Candidate therapeutic agents in a newly established triple wild-type mucosal melanoma cell line.
Shi C; Gu Z; Xu S; Ju H; Wu Y; Han Y; Li J; Li C; Wu J; Wang L; Li J; Zhou G; Ye W; Ren G; Zhang Z; Zhou R
Cancer Commun (Lond); 2022 Jul; 42(7):627-647. PubMed ID: 35666052
[TBL] [Abstract][Full Text] [Related]
2. Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.
Ice RJ; Chen M; Sidorov M; Le Ho T; Woo RWL; Rodriguez-Brotons A; Luu T; Jian D; Kim KB; Leong SP; Kim H; Kim A; Stone D; Nazarian A; Oh A; Tranah GJ; Nosrati M; de Semir D; Dar AA; Chang S; Desprez PY; Kashani-Sabet M; Soroceanu L; McAllister SD
Br J Cancer; 2020 Mar; 122(5):648-657. PubMed ID: 31857724
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations.
Zhou R; Shi C; Tao W; Li J; Wu J; Han Y; Yang G; Gu Z; Xu S; Wang Y; Wang L; Wang Y; Zhou G; Zhang C; Zhang Z; Sun S
Clin Cancer Res; 2019 Jun; 25(12):3548-3560. PubMed ID: 30782616
[TBL] [Abstract][Full Text] [Related]
4. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
Yan J; Wu X; Yu J; Ma M; Yu H; Xu T; Tang H; Xu L; Dai J; Si L; Chi Z; Sheng X; Cui C; Guo J; Kong Y
Melanoma Res; 2018 Dec; 28(6):527-535. PubMed ID: 30086074
[TBL] [Abstract][Full Text] [Related]
6. Validation of a preclinical model for assessment of drug efficacy in melanoma.
Delyon J; Varna M; Feugeas JP; Sadoux A; Yahiaoui S; Podgorniak MP; Leclert G; Dorval SM; Dumaz N; Soulie J; Janin A; Mourah S; Lebbé C
Oncotarget; 2016 Mar; 7(11):13069-81. PubMed ID: 26909610
[TBL] [Abstract][Full Text] [Related]
7. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology.
Segaoula Z; Primot A; Lepretre F; Hedan B; Bouchaert E; Minier K; Marescaux L; Serres F; Galiègue-Zouitina S; André C; Quesnel B; Thuru X; Tierny D
BMC Cancer; 2018 Dec; 18(1):1219. PubMed ID: 30514258
[TBL] [Abstract][Full Text] [Related]
9. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
10. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy.
Kim S; Shin D; Min A; Kim M; Na D; Lee HB; Ryu HS; Yang Y; Woo GU; Lee KH; Lee DW; Kim TY; Lee C; Im SA; Kim JI
J Transl Med; 2021 Jan; 19(1):7. PubMed ID: 33407601
[TBL] [Abstract][Full Text] [Related]
11. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
[TBL] [Abstract][Full Text] [Related]
12. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
13. miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy.
Tang H; Ma M; Dai J; Cui C; Si L; Sheng X; Chi Z; Xu L; Yu S; Xu T; Yan J; Yu H; Yang L; Kong Y; Guo J
J Exp Clin Cancer Res; 2019 May; 38(1):212. PubMed ID: 31118065
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
15. Genomic comparison between an in vitro three-dimensional culture model of melanoma and the original primary tumor.
Kim YS; Park M; Jin S; Jeong GH; Chung YJ; Bang CH
Arch Dermatol Res; 2023 Jul; 315(5):1225-1231. PubMed ID: 36513861
[TBL] [Abstract][Full Text] [Related]
16. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.
Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y
J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777
[TBL] [Abstract][Full Text] [Related]
17. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Garraway LA; Widlund HR; Rubin MA; Getz G; Berger AJ; Ramaswamy S; Beroukhim R; Milner DA; Granter SR; Du J; Lee C; Wagner SN; Li C; Golub TR; Rimm DL; Meyerson ML; Fisher DE; Sellers WR
Nature; 2005 Jul; 436(7047):117-22. PubMed ID: 16001072
[TBL] [Abstract][Full Text] [Related]
18. A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.
Gürgen D; Becker M; Dahlmann M; Flechsig S; Schaeffeler E; Büttner FA; Schmees C; Bohnert R; Bedke J; Schwab M; Wendler JJ; Schostak M; Jandrig B; Walther W; Hoffmann J
Front Oncol; 2022; 12():889789. PubMed ID: 35800063
[TBL] [Abstract][Full Text] [Related]
19. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.
Yu J; Yu J; Wu X; Guo Q; Yin T; Cheng Z; Dai J; Kong Y; Guo J
Clin Sci (Lond); 2020 Jan; 134(2):193-205. PubMed ID: 31919521
[TBL] [Abstract][Full Text] [Related]
20. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
